Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Table 3 FBG levels of patients with T2DM at 6 and 12 months after MSC therapy

Follow-up (months)	Test for heterogeneity		Analysis model	Test for overall effect		WMD or SMD	95% CI
Follow-up (months)	I² (%)	P	Analysis model	Z	P	WMD or SMD	95% CI
6	58	0.09	Random	0.73	0.46	−2.8	(−1.02, 0.47)
12	84	0.01	Random	0.72	0.47	0.54	(−0.93, 2.00)

Abbreviations: FBG fasting blood glucose, T2DM type 2 diabetes, MSCs mesenchymal stem cells, WMD weighted mean difference, SMD standard mean difference

ISSN: 1757-6512